Validación del instrumento de conocimiento sobre enfermedad vascular cerebralen el personal de enfermería (GGA/NICEVC-22) / Validation of the knowledge instrument on cerebrovascular disease in nursing staff (GGA/NICEVC-22) / Validação do instrumento de conhecimento sobre doença cerebrovascular na equipe de enfermagem (GGA/NICEVC-22)

Objetivo: validar un instrumento que evalué el nivel conocimiento del personal de enfermería en la atención al paciente con enfermedad vascular cerebral. Método: estudio longitudinal-proceso con 115 profesionales de enfermería pertenecientes en un hospital de segundo nivel, realizado el periodo de diciembre 2019 a mayo 2020. Muestro no probabilístico por conveniencia. La validación del instrumento se hizo en cinco momentos:1) creación del constructo, 2) validación por 15 jueces expertos, 3) Prueba piloto del instrumento, 4) consistencia interna por el Alpha de Cronbach y 5) validación por análisis factorial con componente rotados, además se aplicó estadística descriptiva. Resultados: el análisis factorial mostró la distribución de los 22 ítems distribuidos en cuatro factores con una varianza explicada de 53.30% y una consistencia interna de α=0.89. Conclusión:los resultados permiten concluir que el instrumento presenta una validez y confiabilidad aceptables, el cual permite evaluar el nivel de conocimiento sobre EVC en el personal de enfermería.

Objective:validar um instrumento que avalia o nível de conhecimento da equipe de enfermagem no cuidado ao paciente com doença cerebrovascular. Method:longitudinal-process study with 115 nursing professionals belonging to a second level hospital, carried out from December 2019 to May 2020. Non-probabilistic sampling for convenience. The validation of the instrument was done in five moments: 1) creation of the construct, 2) validation by 15 expert judges, 3) pilot test of the instrument, 4) internal consistency by Cronbach's Alpha and 5) validation by factorial analysis with rotated components, descriptive statistics were also applied. Results:the factorial analysis showed the distribution of the 22 items distributed in four factors with an explained variance of 53.30% and an internal consistency of α=0.89. Conclusion:the results allow us to conclude that the instrument has acceptable validity and reliability, which allows us to evaluate the level of knowledge about CVD in the nursing staff.

Objetivo:validar um instrumento que avalia o nível de conhecimento da equipe de enfermagem no cuidado ao paciente com doença cerebrovascular. Método:estudode processo longitudinal com 115 profissionais de enfermagem pertencentes a um hospital de segundo nível, realizado no período de dezembro de 2019 a maio de 2020. Amostragem não probabilística por conveniência. A validação do instrumento foi feita em cinco momentos: 1) criação do construto, 2) validação por 15 juízes especialistas, 3) teste piloto do instrumento, 4) consistência interna pelo Alfa de Cronbach e 5) validação por análise fatorial com rodízio componentes., também foi aplicada estatística descritiva. Resultados:a análise fatorial mostrou a distribuição dos 22 itens distribuídos em quatro fatores com variância explicada de 53,30% e consistência interna de α=0,89. Conclusão: os resultados permitem concluir que o instrumento possui validade e confiabilidade aceitáveis, o que permite avaliar o nível de conhecimento sobre DCV na equipe de enfermagem.

Desarrollo de competencias en atención primaria de salud / Development of primary health care competencies

Given that the lack of qualified human resources devoted to primary health care (PHC) is one of the reasons why Alma Ata goals are as yet unattained, PAHO/WHO sponsored the design and implementation of a virtual course for training health care professionals at this level. The course was designed around competencies identified as being necessary for renewing primary care, founded on the premise that providing quality, sustainable services amenable to the public must emanate from professionals who lead the change process at all levels in the system. In this first phase, instruction is aimed at PHC leaders, managers, and other decision makers. The course is offered through the Virtual Public Health Campus and is 27 weeks long.

Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.

We conducted a randomized, double-blind, phase III yellow fever (YF) vaccine trial among 1,107 healthy children in Sullana in northern Peru. The safety and efficacy (by measurement of geometric mean neutralizing antibody titer responses) were determined for two YF vaccines, ARILVAX (n = 738) and YF-VAX(R) (n = 369). Serocon-version rates were higher (94.9%) in ARILVAX than in YF-VAX (90.6%) recipients. The two-sided 95% confidence interval (YF-VAX-ARILVAX) was (-12.8% to -2.5%), indicating that the higher seroconversion rate for Arilvax was significant. Post-vaccination (30-day) mean log(10) neutralization indices were found to be similar for both products: 1.32 for ARILVAX and 1.26 for YF-VAX (P = 0.1404, by analysis of variance). A similar number of subjects in each group reported at least one adverse event (AE); 441 (59.8%) for ARILVAX versus 211 (59.9%) for YF-VAX. Most (591; 96.7%) of these were of a mild nature and resolved without treatment. There were no treatment-related serious AEs. This is the first randomized, double-blind comparison of two YF vaccines in a pediatric population; both vaccines were shown to be highly immunogenic and well-tolerated.